LINC00922

Across TCGA pan-cancer cohorts, LINC00922 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated LINC00922 data layer compared with 24 for mass-spec protein.

The strongest signal is observed in colon adenocarcinoma (COAD), where higher LINC00922 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated LINC00922 expression acts as an unfavorable survival marker.

COAD, LGG, and BRCA are the cancer types where LINC00922 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
COAD	OS	Median	All	0.168	0.801	.003	24	view →
LGG	OS	Median	All	0.177	0.909	<.001	12	view →
BRCA	DFS	Median	All	0.170	0.903	<.001	12	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
BLCA	OS	Median	III,IV	0.187	0.684	.006	3	view →
SKCM	OS	Median	All	0.210	0.781	<.001	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

LINC00922–COAD (OS)

Open the COAD breakdown →